Orion
§ CompareGLP-1-class research compounds

Tirzepatide vs Semaglutide

Tirzepatide is a dual GIP / GLP-1 receptor agonist; Semaglutide acts on GLP-1 alone. Comparing them isolates the contribution of GIP co-agonism.

Research Use Only

Comparison information is provided for in-vitro research reference only. Orion compounds are not FDA-approved and are not for human consumption.

TirzepatideSemaglutide
CAS Number2023788-19-2910463-68-2
Molecular Weight4813.48 g/mol4113.58 g/mol
Sequence
Purity (spec)98.8%98.9%
Size10mg10mg
Half-Life (lit.)120h (lit. 108h–132h)165h (lit. 155h–184h)
Single price$44.99$39.99
10-pack/vial$33.74$29.99
In stock?YesYes

FAQ

What's the chemical difference between Tirzepatide and Semaglutide?

Tirzepatide (CAS 2023788-19-2, MW 4813.48 g/mol) and Semaglutide (CAS 910463-68-2, MW 4113.58 g/mol) are distinct compounds. Tirzepatide is a dual GIP / GLP-1 receptor agonist; Semaglutide acts on GLP-1 alone. Comparing them isolates the contribution of GIP co-agonism.

Which is more commonly used in research?

Both Tirzepatide and Semaglutide appear extensively in GLP-1-class research compounds literature. Comparative-mechanism studies frequently use them as paired references. Selection between them depends on the receptor coverage, kinetics, and assay system of the planned experiment.

What purity does Orion ship for each?

Tirzepatide ships at 98.8%. Semaglutide ships at 98.9%. Each batch is independently tested by reversed-phase HPLC and confirmed by mass spectrometry against the theoretical molecular weight. Every order ships with a batch-specific Certificate of Analysis.

Are these for human use?

No. All Orion research compounds are for in-vitro laboratory research only. They are not FDA-approved for any therapeutic, diagnostic, or clinical use, and they are not for human consumption.

Other comparisons